Review

  • HOME
  • ARTICLE CATEGORY
  • Review
Review
1678
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Clin Mol Hepatol. 2022;28(4):790-801.   Published online May 11, 2022
View: 1853   Download: 275  Citations: 8
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases
Hwang Sik Shin, Baek Gyu Jun, Sang-Wook Yi
Clin Mol Hepatol. 2022;28(4):773-789.   Published online August 8, 2022
View: 1579   Download: 146
1668
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
Clin Mol Hepatol. 2022;28(4):725-738.   Published online March 14, 2022
View: 1758   Download: 171  Citation: 1
1666
The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology
Youngseok Lee, Jong-Hoon Kim
Clin Mol Hepatol. 2022;28(4):706-724.   Published online March 2, 2022
View: 9069   Download: 171  Citations: 3
1692
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clin Mol Hepatol. 2022;28(3):425-472.   Published online July 1, 2022
View: 2623   Download: 185  Citation: 1
1664
RNA interference as a novel treatment strategy for chronic hepatitis B infection
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2022;28(3):408-424.   Published online February 17, 2022
View: 2982   Download: 379  Citations: 7
1658
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance
Mina Komuta
Clin Mol Hepatol. 2022;28(3):396-407.   Published online January 14, 2022
View: 2398   Download: 242  Citation: 1
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Myung Ji Goh, Dong Hyun Sinn
Clin Mol Hepatol. 2022;28(3):380-395.   Published online January 13, 2022
View: 2023   Download: 112
1651
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound
Junghoan Park, Jeong Min Lee, Tae-Hyung Kim, Jeong Hee Yoon
Clin Mol Hepatol. 2022;28(3):362-379.   Published online December 27, 2021
View: 2256   Download: 155
1647
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection
Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee
Clin Mol Hepatol. 2022;28(3):351-361.   Published online November 26, 2021
View: 2306   Download: 168  Citation: 1
1640
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
Pil Soo Sung
Clin Mol Hepatol. 2022;28(3):333-350.   Published online October 19, 2021
View: 13304   Download: 269  Citations: 9
1652
Cost-effectiveness of chronic hepatitis C screening and treatment
Hye Won Lee, Hankil Lee, Beom Kyung Kim, Young Chang, Jae Young Jang, Do Young Kim
Clin Mol Hepatol. 2022;28(2):164-173.   Published online December 27, 2021
View: 2253   Download: 123  Citation: 1
1644
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):150-163.   Published online November 10, 2021
View: 3114   Download: 261  Citations: 12
1641
Approaches to quantifying hepatitis B virus covalently closed circular DNA
Henrik Zhang, Thomas Tu
Clin Mol Hepatol. 2022;28(2):135-149.   Published online October 22, 2021
View: 3609   Download: 276  Citation: 1
1636
The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls
Hae Lim Lee, Sung Won Lee
Clin Mol Hepatol. 2022;28(2):121-134.   Published online September 27, 2021
View: 3054   Download: 258  Citation: 1
1626
Current knowledge about biomarkers of acute kidney injury in liver cirrhosis
Han Ah Lee, Yeon Seok Seo
Clin Mol Hepatol. 2022;28(1):31-46.   Published online August 2, 2021
View: 3311   Download: 202  Citations: 3
1624
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho
Clin Mol Hepatol. 2022;28(1):17-30.   Published online July 20, 2021
View: 5208   Download: 474  Citations: 9
1637
The management of post-transplantation recurrence of hepatocellular carcinoma
Luckshi Rajendran, Tommy Ivanics, Marco PAW Claasen, Hala Muaddi, Gonzalo Sapisochin
Clin Mol Hepatol. 2022;28(1):1-16.   Published online October 5, 2021
View: 3747   Download: 208  Citations: 3
1616
Recent advances in nonalcoholic fatty liver disease metabolomics
Hwi Young Kim
Clin Mol Hepatol. 2021;27(4):553-559.   Published online June 8, 2021
View: 5640   Download: 327  Citations: 7
1617
Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis
Ho Soo Chun, A Reum Choe, Minjong Lee, Yuri Cho, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Clin Mol Hepatol. 2021;27(4):535-552.   Published online June 16, 2021
View: 5926   Download: 415  Citations: 3
1606
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma
Jer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng
Clin Mol Hepatol. 2021;27(4):524-534.   Published online February 23, 2021
View: 10268   Download: 281  Citations: 11
1600
Changes in the epidemiology and management of bacterial infections in cirrhosis
Salvatore Piano, Marta Tonon, Paolo Angeli
Clin Mol Hepatol. 2021;27(3):437-445.   Published online January 28, 2021
View: 3673   Download: 262  Citations: 8
1611
β-blockers in advanced cirrhosis: More friend than enemy
Ki Tae Yoon, Hongqun Liu, Samuel S. Lee
Clin Mol Hepatol. 2021;27(3):425-436.   Published online December 3, 2020
View: 2992   Download: 197  Citations: 4
1578
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, Hideki Fujii, Masaru Enomoto, Norifumi Kawada
Clin Mol Hepatol. 2021;27(3):413-424.   Published online December 3, 2020
View: 9551   Download: 403  Citations: 9
1621
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
Clin Mol Hepatol. 2021;27(3):402-412.   Published online June 23, 2021
View: 3381   Download: 211  Citations: 18
1612
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Clin Mol Hepatol. 2021;27(2):257-269.   Published online March 22, 2021
View: 4614   Download: 355  Citations: 30
1583
Current and future strategies for the treatment of chronic hepatitis C
Omar Alshuwaykh, Paul Y. Kwo
Clin Mol Hepatol. 2021;27(2):246-256.   Published online December 3, 2020
View: 3480   Download: 206  Citations: 5
1580
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Takuji Torimura, Hideki Iwamoto
Clin Mol Hepatol. 2021;27(2):236-245.   Published online December 3, 2020
View: 4954   Download: 287  Citations: 16

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 799
TOTAL : 1046288
Close layer